PROF Profound Medical Corp.

Overview and Growth

Profound Medical Corp. generated $16.10M of revenue in fiscal 2025, with net loss of $42.57M and an operating cash outflow of $38.21M. The $16.10M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Compared with $10.68M in fiscal 2024, revenue recorded a 50.7% year-over-year increase. The company reported diluted EPS of $1.41, adding a shareholder-level measure to the absolute income figures considered below. Diluted EPS increased by 25.9% from $1.12 in fiscal 2024, showing how the earnings change reached shareholders on a per-share basis. At period end, total assets were $77.47M, framing the scale of the company’s operating and financing commitments. The revenue-to-assets relationship was 0.21x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $11.39M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The gross-profit relationship equaled 70.8% of revenue, quantifying the portion retained before operating expenses were recognized. The company recorded an operating loss of $41.25M after the reported operating expense base. Relative to revenue, the operating deficit measured 256.3%, showing the shortfall after operating costs. After all below-operating-line items, the company recorded a net loss of $42.57M for the fiscal year. The net loss equaled 264.4% of revenue, showing the bottom-line deficit relative to the company’s sales base. The pretax result was a loss of $42.32M, establishing the deficit before tax effects. The pretax loss equaled 262.9% of revenue, measuring the pre-tax deficit against sales. Income tax expense totaled $252.00K, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 64.1%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 54.9%.

Liquidity and Capital Structure

The company held $77.47M of assets against $11.04M of liabilities and $66.43M of equity, revealing how the asset base was financed. At period end, current assets of $76.09M compared with current liabilities of $6.08M, defining the company’s short-term resource position. Current assets covered current liabilities by 12.52x, leaving a positive buffer for near-term obligations. The company held $59.72M in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 983.1% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Borrowings totaled $4.50M, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-equity relationship was 0.07x, showing how much debt the company carried for each unit of book equity. Relative to total assets, debt measured 5.8%, showing how much of the asset base was matched by borrowing. Liabilities represented 14.3% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 77.1% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $70.23M in fiscal 2024, the current asset base moved 10.3% and finished higher. Reported equity changed 10.0% from $60.42M in fiscal 2024, placing the current capital base higher year over year.

Cash Flow and Earnings Quality

Operating activities used $38.21M of cash, resulting in an operating cash outflow for the year. The company spent $176.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. The company recorded a $38.38M cash deficit after capital spending for the period. Relative to revenue, the post-investment cash deficit represented 238.4%. The free-cash-flow deficit equaled 49.5% of total assets, placing the cash shortfall against the company’s resource base.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.